SCHEMBL4900880

SCHEMBL4900880

Cc1ccc(NC(=O)CN2CCOCC2)cc1Nc1nccc(-c2ccncc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 17/20 0.54
KIT P10721 7/20 0.54
PDGFRB P09619 5/20 0.54
BCR P11274 14/20 0.53
PDGFRA P16234 5/20 0.53
EGFR P00533 3/20 0.51
ABL2 P42684 2/20 0.51
PLK4 O00444 1/20 0.51
DDX3X O00571 1/20 0.51
GAK O14976 1/20 0.51
SLC22A2 O15244 1/20 0.51
MAPK13 O15264 1/20 0.51
CA12 O43570 1/20 0.51
SLC22A3 O75751 1/20 0.51
ABCB11 O95342 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
LMNA P02545 1/20 0.51
ALB P02768 1/20 0.51
RAF1 P04049 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4894484 0.91 ABL1 (0.67) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4903153 0.90 ABL1 (0.63) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4903416 0.87 JAK2 (0.62) KITPDGFRBPDGFRAPLK4GAK
SCHEMBL4896431 0.87 ABL1 (0.52) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4901647 0.86 ALDH1A1 (0.54) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4902913 0.85 ABL1 (0.57) ABL1PDGFRBBCRPDGFRAABL2
SCHEMBL4892565 0.84 ABL1 (0.54) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4892416 0.82 ABL1 (0.63) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4903276 0.81 ABL1 (0.77) ABL1KITPDGFRBBCRPDGFRA
SCHEMBL4905663 0.81 PDGFRA (0.62) ABL1KITPDGFRBBCRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885KIT 969/4885PDGFRB 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.